Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Public ClinicalTrials.gov record NCT04379596. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants With HER2-expressing Gastric Cancer (DESTINY-Gastric-03)
Study identification
- NCT ID
- NCT04379596
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 450 participants
Conditions and interventions
Conditions
Interventions
- Capecitabine Drug
- Cisplatin Drug
- Durvalumab Biological
- Fluorouracil (5-FU) Drug
- Oxaliplatin Drug
- Pembrolizumab Biological
- Rilvegostomig Biological
- Trastuzumab Biological
- Trastuzumab deruxtecan Drug
- Volrustomig Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2, 2020
- Primary completion
- May 31, 2027
- Completion
- May 31, 2027
- Last update posted
- Feb 22, 2026
2020 – 2027
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Santa Monica | California | 90404 | Withdrawn |
| Research Site | Westwood | Kansas | 66205 | Withdrawn |
| Research Site | Baltimore | Maryland | 21287 | Recruiting |
| Research Site | Boston | Massachusetts | 02114 | Withdrawn |
| Research Site | Boston | Massachusetts | 02215 | Recruiting |
| Research Site | Ann Arbor | Michigan | 48109 | Withdrawn |
| Research Site | New York | New York | 10065 | Recruiting |
| Research Site | Durham | North Carolina | 27710 | Withdrawn |
| Research Site | Houston | Texas | 77090 | Recruiting |
| Research Site | Fairfax | Virginia | 22031 | Withdrawn |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 90 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04379596, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 22, 2026 · Synced May 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04379596 live on ClinicalTrials.gov.